A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)

Brief description of study

The purpose of the trial is to assess the safety (side effects) and efficacy (benefits) of the investigational drug relacorilant (also referred to as CORT125134) together with the chemotherapy drug, nab-paclitaxel, in patients with metastatic pancreatic cancer. We want to know if the addition of relacorilant to nab-paclitaxel controls the cancer and how tumors respond to the combination of relacorilant and nab-paclitaxel. Relacorilant is an investigational drug in this study because it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.

Clinical Study Identifier: s19-01235
ClinicalTrials.gov Identifier: NCT04329949
Principal Investigator: Paul E. Oberstein.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.